4.5 Editorial Material

Tedizolid (TR-701): a new oxazolidinone with enhanced potency

Journal

EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 4, Pages 515-522

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2012.660250

Keywords

oxazolidinone; skin and skin structure infections; Staphylococcus aureus; tedizolid

Ask authors/readers for more resources

Introduction: Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid. Areas covered: This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics/pharmacodynamics, clinical efficacy and safety are all addressed. Expert opinion: Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available